

To whom it may concern,

(Vul in: Naam) is known with the atypical hemolytic uremic syndrome (aHUS). He/she is on eculizumab treatment, a monoclonal antibody against complement C5, every (vul in: aantal) week intravenously.

Nowadays he/she is in remission, but every aHUS patient can develop a relapse of aHUS (hemolytic anemia, thrombocytopenia and acute renal failure). Often there will be a trigger, mostly an infection. As every aHUS patient on eculizumab treatment, he/she is at risk for an infection with *Neisseria meningococcal* bacterium and other infections.

In case of illness, fever or macroscopic hematuria or when there is doubt about this patient's health, please check if there is a relapse of aHUS (hemolytic anemia, thrombocytopenia and acute renal failure, urine, blood pressure) or a severe infection. Be aware of meningococcal infection.

This patient is on the following medications:

(overzicht medicijnen invullen)

If there are any medical concerns, without hesitation contact (vul in: naam en contactgegevens arts of afdeling, naam ziekenhuis) and ask for the nephrologist on call.